Skip to main content
Cyfuse Biomedical K.K. logo

Cyfuse Biomedical K.K. — Investor Relations & Filings

Ticker · 4892 ISIN · JP3311800001 T Manufacturing
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-03-27 Regulatory Filings
Country JP Japan
Listing T 4892

About Cyfuse Biomedical K.K.

https://en.cyfusebio.com/

Cyfuse Biomedical K.K. is a research and development company specializing in regenerative medicine through its proprietary bio 3D printing platform technology. The company's core innovation is a scaffold-free method for fabricating three-dimensional tissues and organs by fusing cellular aggregates, known as spheroids. This approach allows for the creation of complex biological structures using cells exclusively. Cyfuse develops, manufactures, and commercializes its bio 3D printers, including the Regenova® and S-PIKE® systems. These technologies are aimed at advancing applications in drug discovery, preclinical research, and the development of cellular products for therapeutic tissue and organ regeneration.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 70% confidence The document is a brief confirmation letter (確認書) filed under the Financial Instruments and Exchange Act to the Kanto Finance Bureau, attesting to the accuracy of the company’s FY16 Securities Report. It is not the Securities Report itself, nor any other specific report type (e.g., AGM materials, earnings release). This small regulatory submission falls into the general “Regulatory Filings” category.
2026-03-27 Japanese
有価証券報告書－第16期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains the official header, fiscal period (2025-01-01 to 2025-12-31), company information, financial highlights, and historical development details. It is a comprehensive annual financial report filed with the Kanto Local Finance Bureau. FY 2025
2026-03-27 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by Cyfuse Biomedical K.K. It details a third-party allotment of shares (capital increase) to Kuraray Co., Ltd. This type of filing is a regulatory requirement for issuing new securities in Japan. Since it is a formal regulatory filing regarding capital changes and share issuance, it falls under the 'Share Issue/Capital Change' category.
2025-12-24 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of the contents of a Semi-Annual Report (Hankishokokusho) for the period ending June 30, 2025. Since this is a regulatory filing required by law to accompany financial reports and does not fit into the specific categories of the reports themselves, it falls under the general regulatory filing category.
2025-08-14 Japanese
半期報告書－第16期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Cyfuse Biomedical K.K. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis (MDA), and corporate information for the interim period (January 1, 2025, to June 30, 2025). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-14 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 98% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). It explicitly details the offering of "新株予約権証券" (Stock Acquisition Rights Certificates) and provides extensive information regarding the offering conditions, the nature of the rights, exercise prices, capital structure adjustments, and the purpose of the fundraising, which is related to the company's core business (regenerative medicine/3D cell products). This structure and content strongly indicate a filing related to the issuance of new securities, which aligns with the definition of a Capital/Financing Update (CAP) or potentially a specific type of registration statement. Given the detailed nature of the offering terms for stock acquisition rights, 'CAP' (Capital/Financing Update) is the most appropriate classification among the provided options, as it covers fundraising and capital structure changes. It is a full registration document, not just a brief announcement (RPA/RNS).
2025-05-30 Japanese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.